Therefore, in addition to the established endpoint of conversion to motor PD, it seems reasonable to seriously consider cognitive endpoints as additional outcomes for clinical trials and studies of GBA1NMC, in particular given that GBA1 mutations not only confer risk for motor PD but also for DLB as well as cognitive decline eventually resulting in dementia. Here, GBA1 is linked to Parkinson disease.